Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co IncfiledCriticalMerck & Co Inc
Priority to DO2003000770ApriorityCriticalpatent/DOP2003000770A/en
Publication of DOP2003000770ApublicationCriticalpatent/DOP2003000770A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity often associated with type 2 diabetes.
DO2003000770A2003-12-012003-12-01
INDOLES WITH ANTIBIABETIC ACTIVITY
DOP2003000770A
(en)
3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy) -cyclohexanecarbonylamino) -morbic acid derivatives and similar compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis